In situ forming IPN hydrogels of calcium alginate and dextran-HEMA for biomedical applications.
In situ forming hydrogels, which allow for the modulation of physico-chemical properties, and in which cell response can be tailored, are providing new opportunities for biomedical applications. Here, we describe interpenetrating polymer networks (IPNs) based on a physical network of calcium alginate (Alg-Ca), interpenetrated with a chemical one based on hydroxyethyl-methacrylate-derivatized dextran (dex-HEMA). IPNs with different concentration and degree of substitution of dex-HEMA were characterized and evaluated for protein release as well as for the behavior of embedded cells. The results demonstrated that the properties of the semi-IPNs, which are obtained by dissolution of dex-HEMA chains into the Alg-Ca hydrogels, would allow for injection of these hydrogels. Degradation times of the IPNs after photocross-linking could be tailored from 15 to 180 days by the concentration and the degree of substitution of dex-HEMA. Further, after an initial burst release, bovine serum albumin was gradually released from the IPNs over approximately 15 days. Encapsulation of expanded chondrocytes in the IPNs revealed that cells remained viable and, depending on the composition, were able to redifferentiate, as was demonstrated by the deposition of collagen type II. These results demonstrate that these IPNs are attractive materials for pharmaceutical and biomedical applications due to their tailorable mechanical and degradation characteristics, their release kinetics and biocompatibility.
Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.
Laura
L
Pescosolido
Tina
T
Vermonden
Jos
J
Malda
Roberta
R
Censi
Wouter J A
WJ
Dhert
Franco
F
Alhaique
Wim E
WE
Hennink
Pietro
P
Matricardi
D000464:Alginates / Q000494:pharmacology*; D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D002417:Cattle; D002470:Cell Survival / Q000187:drug effects; D018914:Cells, Immobilized / Q000166:cytology / Q000187:drug effects; D055598:Chemical Phenomena / Q000187:drug effects; D019902:Chondrocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D003911:Dextrans / Q000737:chemistry / Q000494:pharmacology*; D055119:Elastic Modulus / Q000187:drug effects; D020723:Glucuronic Acid / Q000494:pharmacology; D006603:Hexuronic Acids / Q000494:pharmacology; D006736:Horses; D020100:Hydrogels / Q000737:chemistry / Q000494:pharmacology*; D008689:Methacrylates / Q000737:chemistry / Q000494:pharmacology*; D010619:Phenazines / Q000378:metabolism; D011108:Polymers / Q000494:pharmacology*; D012710:Serum Albumin, Bovine / Q000378:metabolism; D013194:Staining and Labeling
D000464:Alginates; D001672:Biocompatible Materials; D015415:Biomarkers; D003911:Dextrans; D006603:Hexuronic Acids; D020100:Hydrogels; D008689:Methacrylates; D010619:Phenazines; D011108:Polymers; C508284:dextran hydroxyethyl methacrylate; D012710:Serum Albumin, Bovine; D020723:Glucuronic Acid; C009195:safranine T